Latest news
April 18, 2024

− Results from the Phase 3 SELECT-GCA study showed 46 percent of patients with giant cell arteritis (GCA) who were treated with upadacitinib (RINVOQ®; 15 mg) with a 26-week steroid taper...

April 12, 2024

- Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine - Seventy percent of...

April 09, 2024

From the makers of BOTOX® Cosmetic (onabotulinumtoxinA), two new SkinMedica® acne products help address skin blemishes and can be combined with in-office DiamondGlow® IRVINE, Calif., April 9,...

More »

AbbVie on Twitter

Looking for more news from AbbVie? Follow us on social media.


Advanced Search
Show 5102550100 per page
Our history

Explore where we've been and how we continue to go beyond medicine to make a remarkable impact. Learn more

Societal impact

Our commitment to science is a commitment to better our society. Read our 2022 ESG report

Ratings and recognition

We've been honored to receive some of the most prestigious ratings and recognnitions in the industry. Learn more

Annual report

See our latest 2023 Annual Report on Form 10-K. Learn more



The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?